L 752860
Latest Information Update: 22 Jan 2008
Price :
$50 *
At a glance
- Originator Merck & Co
- Class Antirheumatics; Nonsteroidal anti-inflammatories
- Mechanism of Action Cyclo-oxygenase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 25 Mar 1999 No-Development-Reported for Inflammation in USA (PO)
- 09 Sep 1996 Phase-I clinical trials for Inflammation in USA (PO)